Study found 99% of vaccinated people in Serrana seroconverted.The indicator was higher than the results from the clinical trials from phases one and two of CoronaVac, showing seroconversion at around 97 and 98 percent, respectively, depending on the dose.
“The immunogenicity data leave uncertainties regarding how long the protection provided by the inoculation lasts,” Anvisa stated in a note.
Brazil’s Ministry of Health on Thursday (Mar. 25) is starting to distribute a new batch of vaccines against COVID-19. Doses total 4.2 million, including the first shipment from the international consortium Covax Facility—1 million doses—and a new batch of Coronavac produced in Brazil by Butantan Institute—3.2 million
Priority groups in phase one are being immunized, among whom health care workers, institutionalized people (patients in a home) aged 60 or older, institutionalized people with disabilities, and indigenous people living in villages.